Development of an FDA guidance document for clinical trials in SLE

Abstract

To make the process of developing new therapeutic agents more efficient, it is critical that investigators and industry sponsors understand in advance what information they will need to provide to the US Food and Drug Administration (FDA) in order to license and market their product. To facilitate that process, the FDA publishes guidance documents describing current thinking about various issues that arise at all stages of product development. The FDA is currently in the process of formulating a guidance document about clinical development programs for systemic lupus erythematosus (SLE). The goal of this document is to describe some of the types of clinical trials that could be used to demonstrate safety and efficacy of therapeutic agents in SLE.

Keywords

clinical trials disease activity lupus nephritis

Get full access to this article

View all access options for this article.

References

The Food and Drug Administration's Development, Issuance, and Use of Guidance Documents . Federal Register February 27, 1997; 62: 8961 ‐ 8972 , www.fda.gov/cder/guidance/index.htm.

Design and assessment of clinical trials of drugs, biologics and devices that are being developed for treatment of systemic lupus erythematosus FDA Arthritis Advisory Committee. Silver Spring MD, 1999, www.fda.gov/cder99t.htm%23Arthritis.

Guidance for Industry: Clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis (RA). FDA guidance document, 1999, www.fda.gov/cder/guidance=.

Felson DT , Anderson JJ , Lange ML , Wells G , LaValley MP . Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998; 41: 1564 ‐ 1570 .

Strand V , Gladman D , Isenberg D et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus . J Rheumatol 1999; 26: 490 ‐ 497 .

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . The Canadian Hydroxychloroquine Study Group . N Engl J Med 1991; 324: 150 ‐ 154 .

Fleming TR , DeMets DL . Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605 ‐ 613 .

Boumpas DT , Barlow JE . Outcome criteria for lupus nephritis trials: a critical overview . Lupus 1998; 7: 622 ‐ 629 .

Levey AS , Lan SP , Corwin HL et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide . Ann Intern Med 1992; 116: 114 ‐ 123 ,

10.

Moroni G , Quaglini S , Maccario M , Banfi G , Ponticelli C . `Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis . Kidney Int 1996; 50: 2047 ‐ 2053 .